99 related articles for article (PubMed ID: 19783286)
1. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
[TBL] [Abstract][Full Text] [Related]
2. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.
Mabuchi S; Ugaki H; Isohashi F; Yoshioka Y; Temma K; Yada-Hashimoto N; Takeda T; Yamamoto T; Yoshino K; Nakajima R; Kuragaki C; Morishige K; Enomoto T; Inoue T; Kimura T
Gynecol Obstet Invest; 2010; 69(4):224-232. PubMed ID: 20068328
[TBL] [Abstract][Full Text] [Related]
3. The Therapeutic Value of Adjuvant Chemotherapy after Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer.
Wang YN; Zhong ML; Liang MR; Yang JT; Zeng SY
Gynecol Obstet Invest; 2023; 88(5):286-293. PubMed ID: 37497957
[TBL] [Abstract][Full Text] [Related]
4. Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer.
Zhang Y; Fan S; Shan M; Zou W; Feng Y; Hou T; Liu X; Wang J
Sci Rep; 2023 Jun; 13(1):9352. PubMed ID: 37291330
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of consolidation chemotherapy after adjuvant therapy in stage IB-IIA cervical cancer patients with risk factors: a retrospective single-center study.
Wang J; Guo H; Yang J; Mao J; Wang Y; Gao R; Yan X; Wang J
Front Oncol; 2024; 14():1374195. PubMed ID: 38577338
[TBL] [Abstract][Full Text] [Related]
6. Nedaplatin: a radiosensitizing agent for patients with cervical cancer.
Mabuchi S; Kimura T
Chemother Res Pract; 2011; 2011():963159. PubMed ID: 22312560
[TBL] [Abstract][Full Text] [Related]
7. Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer.
Nishimura H; Amano T; Yoneoka Y; Tsuji S; Taga Y; Aki M; Uno M; Moritani S; Murakami R; Kato T; Murakami T
J Gynecol Oncol; 2024 May; ():. PubMed ID: 38725235
[TBL] [Abstract][Full Text] [Related]
8. Early-stage intermediate-risk-the group with the most heterogenous management among patients with cervical cancer.
Cibula D
Int J Gynecol Cancer; 2022 Sep; ():. PubMed ID: 36100280
[No Abstract] [Full Text] [Related]
9. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.
Zhou Y; Wang W; Tang J; Hu K; Zhang F
BMC Cancer; 2024 Apr; 24(1):548. PubMed ID: 38689248
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Survival Outcomes of Minimally Invasive Surgery with Open Surgery in Patients with Uterine-Confined and Node-Negative Cervical Cancer: A Population-Based Study.
Mabuchi S; Sasano T; Komura N; Maeda M; Matsuzaki S; Hisa T; Kamiura S; Morishima T; Miyashiro I
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345093
[TBL] [Abstract][Full Text] [Related]
12. A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.
Yang X; Ren H; Li Z; Zhang L; Shao Y; Li H; Yang X; Sun Y; Zhang X; Wang Z; Fu J
ESMO Open; 2022 Oct; 7(5):100565. PubMed ID: 35994789
[TBL] [Abstract][Full Text] [Related]
13. Impact of a reduction in follow-up frequency on life expectancy in uterine cervical cancer patients.
Matsumoto Y; Mabuchi S; Isohashi F; Komura N; Ogawa K; Kimura T
Int J Clin Oncol; 2020 Jun; 25(6):1170-1177. PubMed ID: 32152766
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin concurrent chemoradiotherapy vs adjuvant radiation in stage IB/IIA cervical cancer with intermediate risk factors, treated with radical surgery: a retrospective study.
Sun HY; Tang Q; Chen JH; Lv XJ; Tu YQ; Yan DD
Onco Targets Ther; 2018; 11():1149-1155. PubMed ID: 29563803
[TBL] [Abstract][Full Text] [Related]
15. Comparison of chemoradiotherapy with and without brachytherapy as adjuvant therapy after radical surgery in early-stage cervical cancer with poor prognostic factors: An observational study.
Lan ML; Yu X; Xiao H; Zhou P; Hu N; Liu Y; Wang G
Medicine (Baltimore); 2017 Nov; 96(46):e8384. PubMed ID: 29145247
[TBL] [Abstract][Full Text] [Related]
16. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
18. Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy in early-stage cervical cancer patients with intermediate risk factors.
Yu H; Zhang L; Du X; Sheng X
Onco Targets Ther; 2016; 9():7331-7335. PubMed ID: 27942225
[TBL] [Abstract][Full Text] [Related]
19. A comparative dosimetric study of volumetric-modulated arc therapy vs. fixed field intensity-modulated radiotherapy in postoperative irradiation of stage IB-IIA high-risk cervical cancer.
Qiao L; Cheng J; Liang N; Xie J; Luo H; Zhang J
Oncol Lett; 2016 Feb; 11(2):959-964. PubMed ID: 26893675
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
